Rights statement: https://www.cambridge.org/core/journals/china-quarterly/article/antidepressant-advertising-in-china-and-the-uk-the-strengths-and-limits-of-policy-learning/21A7153E89FF33D0AB56E1928AEB5714 The final, definitive version of this article has been published in the Journal, China Quarterly, 239, pp 752-774 2019, © 2019 Cambridge University Press.
Accepted author manuscript, 1.25 MB, PDF document
Available under license: CC BY: Creative Commons Attribution 4.0 International License
Final published version
Research output: Contribution to Journal/Magazine › Journal article › peer-review
Research output: Contribution to Journal/Magazine › Journal article › peer-review
}
TY - JOUR
T1 - Antidepressant advertising in China and the UK
T2 - The strengths and limits of policy learning
AU - Geyer, Robert Ralph
AU - Wang, Fang
N1 - https://www.cambridge.org/core/journals/china-quarterly/article/antidepressant-advertising-in-china-and-the-uk-the-strengths-and-limits-of-policy-learning/21A7153E89FF33D0AB56E1928AEB5714 The final, definitive version of this article has been published in the Journal, China Quarterly, 239, pp 752-774 2019, © 2019 Cambridge University Press.
PY - 2019/9/1
Y1 - 2019/9/1
N2 - China is expected to become one of the largest markets for prescription drugs in the world and pharmaceutical advertising is becoming increasingly important, particularly in the socially and culturally contested area of mental health. This article briefly explores the background of drug advertising policies in China and the UK and focuses on the distinctive challenges of antidepressant drug regulation. Then, using tools of critical discourse analysis, it examines Chinese antidepressant adverts, and compares them with relevant British adverts. The findings indicate that, relative to the UK, Chinese antidepressant adverts are generally oversimplified, and the critical information concerning the concepts of caution, danger and adverse effects are underrepresented. However, there are many interdependent factors that contribute to the distinctive Chinese antidepressant drug regulatory regime. Hence, Chinese policymakers must maintain a delicate balance between learning from Western regulatory regimes, but also avoiding borrowing too heavily from them.
AB - China is expected to become one of the largest markets for prescription drugs in the world and pharmaceutical advertising is becoming increasingly important, particularly in the socially and culturally contested area of mental health. This article briefly explores the background of drug advertising policies in China and the UK and focuses on the distinctive challenges of antidepressant drug regulation. Then, using tools of critical discourse analysis, it examines Chinese antidepressant adverts, and compares them with relevant British adverts. The findings indicate that, relative to the UK, Chinese antidepressant adverts are generally oversimplified, and the critical information concerning the concepts of caution, danger and adverse effects are underrepresented. However, there are many interdependent factors that contribute to the distinctive Chinese antidepressant drug regulatory regime. Hence, Chinese policymakers must maintain a delicate balance between learning from Western regulatory regimes, but also avoiding borrowing too heavily from them.
KW - antidepressant advertising
KW - China
KW - critical discourse analysis (CDA)
KW - prescription drug regulation
KW - policy learning
U2 - 10.1017/S0305741019000043
DO - 10.1017/S0305741019000043
M3 - Journal article
VL - 239
SP - 752
EP - 774
JO - China Quarterly
JF - China Quarterly
SN - 0305-7410
ER -